August 2012
-
MicroDose Therapeutx has initiated a Phase 1 clinical trial of MDT-637, an inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV) that is delivered using the company’s novel dry powder… Read more . . .
-
Former SkyePharma CEO and current Executive Chairman of PolyTherics Ken Cunningham has joined the Board of Directors of inhaled drug developer Prosonix as a Non-Executive Director. Cunningham will also serve as Chair of the Prosonix… Read more . . .
-
Two posters presented by Pearl Therapeutics at the 2011 European Respiratory Society meeting show additional data from a Phase 2b study demonstrating that Pearl’s glycopyrrolate (GP)/fomoterol fumarate (FF) fixed combination metered dose inhaler and its… Read more . . .
-
Shortly after announcing positive Phase 2a results for its glycopyrrolate inhalation solution, Elevation Pharmaceuticals, announced that it has appointed Jaisim Shah as Senior Vice President and Chief Business Officer and Pravin Soni as Senior Vice… Read more . . .
-
Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled… Read more . . .
-
According to Mundipharma, three Phase 3 studies of the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) have demonstrated that the product “had comparable efficacy in improving the lung function and a similar safety profile… Read more . . .
-
Elevation Pharmaceuticals has presented positive results from a Phase 2a study of its glycopyrrolate inhalation solution in patients with moderate to severe COPD at the European Respiratory Society (ERS) meeting in Amsterdam. If Elevation can… Read more . . .
-
MannKind Corporation has announced a proposed offer of senior secured discount notes, due 2017, that would yield approximately $370 million. The company says that it would use the money to complete Phase 3 clinical trials… Read more . . .
-
Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its… Read more . . .
-
Armstrong Pharmaceuticals, the manufacturer of the over-the-counter epinephrine MDI Primatene Mist, has been warning consumers to stock up on the product prior to its phaseout at the end of 2011, . . . .Read more Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland